Ann: ArTiMist Appeal Reasons For Decision, page-47

Remember KCL that the efficacy of the technology is not one thing. It is not proven once. It has to be proven with each drug, because each drug is very different chemically and the way it works and the effect of barriers for that specific drug.

We don't "have a bunch of high-level, disinterested cardigans telling the world that SUDA's oro-mucosal drug delivery system is that good that it could be a game-changer on a global level". We have them saying it delivered one drug that did not get approved. That is a very different thing.

We need to release studies showing it can do this for specific drugs. At this point, Pfizer haven't pushed ahead with their OTC's. Why? it is not believable they got too busy, because a different delivery for a block-buster of theirs is money in the bank, not least because it extends patent life for the pharma.

I remain hopeful, but not convinced until we see results. I suspect the market feels the same.